Fresh analysis indicates that patients who come off popular weight-loss injections like semaglutide or tirzepatide tend to recover reduced body mass at a significantly accelerated pace than those who halt traditional diet and exercise plans.
Findings released in a major health publication demonstrates that while overweight people can lose about a fifth of their body weight while undergoing treatment, the weight is regained at an estimated rate of nearly a kilo each month once they quit.
"People buying such treatments should be aware of the risk of quick weight regain when the treatment is stopped," cautioned expert Dr. Susan Jebb.
Such speed of recovery means a return to original weight in about 18 months.
Comparing Approaches
The study, which looked at 37 of studies involving thousands of patients, compared the outcomes of these new drugs with conventional dieting.
The team note that individuals who shed pounds through diet and exercise generally experience a more gradual creep back—approximately 100 grams monthly—once they finish.
Understanding the Rapid Rebound
Doctors propose the way of the drugs accounts for the heightened regain.
GLP-1 drugs copy a natural hormone called GLP-1, which moderates hunger.
"Sustained high doses of the hormone concentrations far above than normal could lead to the system to generate a reduced amount of its endogenous hormone, and may also diminish sensitivity to its effects," explained Dr. Adam Collins, a nutrition expert.
"Discontinuation of this GLP-1 'fix' leads to appetite is unsuppressed, making binge eating far more likely."
A Chronic Disease?
Medical guidelines suggest the injections for people with weight-linked health risks, accompanied by recommended lifestyle changes.
Many experts say that, due to the likelihood of relapse, the treatment should be considered long-term.
This opinion is supported by drug manufacturers, who say that the findings "emphasize the chronic character of obesity," similar to managing diseases like diabetes.
Patient Accounts
Users who have discontinued the medication report a sudden resurgence of appetite.
"It was like a switch activating and I was suddenly starving," described one woman.
This challenge is worsened if patients have not established sustainable lifestyle or habit modifications during therapy.
Significant Adoption
Recent estimates show that a significant number of people in the UK have tried weight-loss jabs in the last 12 months, with interest remaining high.
- Use is higher among women compared to men.
- The middle-aged demographic shows the highest usage rates.
- Many obtain the medications through private healthcare rather than the NHS.
In conclusion, clinicians caution that while GLP-1 drugs are potent tools for shedding pounds, they are not a magic cure and lasting health benefits likely depends on integrated lifestyle management.
